Navigation Links
ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
Date:1/28/2010

f inflammation by means of its receptor (C5aR). This system is active in many diseases, thus making C5aR an attractive target for small molecule therapeutics.  Given molecular structure similarities between the C5aR and chemokine receptors, ChemoCentryx researchers successfully applied the Company's proprietary drug discovery technologies to the design of small molecule C5aR antagonists and selected CCX168 based on its potency, selectivity and favorable pharmacokinetics.  C5aR is one of four defined chemokine and chemoattractant receptor projects covered under an alliance between ChemoCentryx and GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).  

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. CCX025, also a CCR9 antagonist, has to date successfully completed a Phase I clinical program.  Additional clinical programs include CCX140, which targets the CCR2 receptor, expected to enter Phase II clinical development in the first quarter
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 /CNW Telbec/ - Ergoresearch Ltd ("Ergoresearch" ... for accelerated growth in terms of sales and profitability. ... $17,862,341. Net income amounted to $1,230,153. The EBITDA reached ... time in the Company,s history. With the ... forces of its subsidiaries, merging in September 2014 Clinique ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
(Date:10/31/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results and ... 11:30 a.m. ET / 8:30 a.m. PTWhere: , ... Simply log onto our website listed above. If you ... replay of the webcast will be available for a ...
Breaking Medicine Technology:Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3
... Jan. 19, 2012 /PRNewswire/ --  Terumo Cardiovascular Systems announced ... with LAAx, Inc. to distribute the TigerPaw® System II, ... The TigerPaw System II is indicated ... visualization, in conjunction with other open cardiac procedures.  It ...
... SAN DIEGO, Jan. 19, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... an underwritten public offering of 9,500,000 shares of its ... $8.10 per share. The gross proceeds to Neurocrine from ... other offering expenses payable by Neurocrine, are expected to ...
Cached Medicine Technology:Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 3
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... New York (PRWEB) October 31, 2014 ... Mineola Eye in Garden City, Long Island and the ... to their medical staff, according to North Shore Eye ... is the Emeritus Acting Chairman of the Department of ... and successful practice in Garden City for more than ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 FindSurrogateMother.com ... most remarkable gifts of life — building a family ... extraordinary surrogate mothers and donors with hopeful intended parents ... unforeseen circumstances. , It’s a collective aptitude of surrogate ... surrogacy lawyers, and fertility clinics that help provide these ...
(Date:10/31/2014)... 31, 2014 BCC Research ( http://www.bccresearch.com ) ... QUALITY MARKET , the U.S. indoor air quality (IAQ) market ... a compound annual growth rate (CAGR) of 7% over the ... grow at a CAGR of 7.4%. , Since 2012, ... mold, the outbreak of infectious diseases such as bird flu ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... A study was conducted by Nathan Thielman, M.D, Duke University ... effective in preventing HIV infections than those which charge a ... testing center and is therefore a very efficient method. ... free testing was conducted by The Duke researchers. Before that ...
... Plans have been announced by the Indian Government to ... which will highlight the achievements of Indian Scientists, //in ... science. The name of the new initiative of the ... for producing a one-hour film and 15 two-minute shorts ...
... most common cancer next to breast cancer in women and ... of cervical cancer would help in early treatment //and help ... cytologic screening test known as Pap smear test is used ... state and could detect early diagnosis. Women above the age ...
... have committed suicide five months ago using a lethal dose of ... degenerative disease// which made her life very traumatic and she had ... to escape from her traumatic pain so she went to Dignitas ... Irwin and Jessica Reid. ,Mrs. Jessica Reid who accompanied ...
... Bio-functional garments like stockings with aloe vera, T-shirts with ... been developed as the textile industry takes its cue ... garments an additional function in addition to keeping the ... their promises is a contentious matter. Experts also fear ...
... bond exists among siblings, even though they compete with each ... parents. The relationship which exists between siblings is very // ... do not welcome the birth of a new baby in ... among siblings. Their relationship has become more like partnerships, partly ...
Cached Medicine News:Health News:Free HIV Tests Brings Crowd to the Testing Centers 2Health News:Scented Garments Hit The Market 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: